1003-P: Clinical Response (HbA1c ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1c and Body Weight in the SUSTAIN Program

Autor: Julie F. Larsen, Signe Harring Østoft, Vanita R. Aroda, Rosangela Rea, Danny Sugimoto, Uwe Ziegler, Tina Vilsbøll

Publikováno v: Diabetes. 68

The SUSTAIN clinical development program assessed semaglutide once weekly, a glucagon-like peptide-1 (GLP-1) analog, across the continuum of type 2 diabetes (T2D) care, including in drug-naïve subjects and those on a background of oral antidiabetic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae9a349aea586cd56c063e75b1797fac
https://doi.org/10.2337/db19-1003-p

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects

Autor: Signe Harring Østoft, Carolyn F. Deacon, Filip K. Knop, Tina Vilsbøll, Nicolai Rhee, Jens J. Holst

Publikováno v: European Journal of Endocrinology. 171:353-362

ObjectiveInhibition of dipeptidyl peptidase 4 (DPP4) is thought to intensify the physiological effects of the incretin hormones. We investigated the effects of DPP4 inhibition on plasma levels of glucose-dependent insulinotropic polypeptide (GIP), gl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a70328d6698d03b3d6a1fbc526de2626
https://doi.org/10.1530/eje-14-0314

Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential

Autor: Signe Harring, Østoft

Publikováno v: Danish medical journal. 62(9)

Maturity onset diabetes of the young (MODY) designates monogenic forms of non-autoimmune diabetes characterised by autosomal dominant inheritance, non-insulin dependent diabetes at onset and diagnosis often before 25 years of age. MODY constitutes ge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bf12706f77fa7aed60c4822bcf35aa45
https://pubmed.ncbi.nlm.nih.gov/26324089

Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial

Autor: Jens Faber, Jens J. Holst, Torben Hansen, Tina Vilsbøll, Signe Harring Østoft, Filip K. Knop, Oluf Pedersen, Jonatan I. Bagger

Publikováno v: BASE-Bielefeld Academic Search Engine
Ostoft, S H, Bagger, J I, Hansen, T, Pedersen, O, Faber, J, Holst, J J, Knop, F K & Vilsboll, T 2014, ' Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist : A Double-Blind, Randomized, Crossover Trial ', Diabetes Care, vol. 37, no. 7, pp. 1797-1805 . https://doi.org/10.2337/dc13-3007

OBJECTIVE The most common form of maturity-onset diabetes of the young (MODY), hepatocyte nuclear factor 1 alpha (HNF1A diabetes: MODY3) is often treated with sulfonylureas that confer a high risk of hypoglycemia. We evaluated treatment with GLP-1 re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db4311b570f6c87b92fb4d5fd9acfd46
https://pubmed.ncbi.nlm.nih.gov/24929431